Compare Affirm Holdings Inc (AFRM) vs Hims and Hers Health Inc (HIMS) Price & Performance

AFRM trades at $75.25, down 1.74% on the day, with a bullish technical signal supported by moving averages. The company reported strong revenue growth to $3.22B in 2025, turning profitable with net income of $52.19M, and has beaten EPS estimates in recent quarters. Positive sentiment is driven by analyst optimism and expanding merchant partnerships.

Outlook remains favorable with a consensus price target of $96.00, indicating 28% upside. Risks include high valuation multiples (P/E 68.41) and sensitivity to interest rate changes. Continued execution on growth and profitability will be key for stock performance.

Hims & Hers Health stock trades at $31.59, up 6.51% today, showing strong momentum. The technical outlook is bullish, with the price above key moving averages and support at $30. Fundamentally, revenue growth is robust at 40% year-over-year in Q2 2026 (MarketBeat, 2026-08-10), but profitability remains challenged with a net loss margin of -0.56% in 2026. The company raised its annual revenue forecast to $3.1–3.3 billion (WSJ, 2026-08-10), reflecting confidence in subscriber growth and expansion into weight-loss treatments.

The investment outlook is mixed: strong revenue growth and bullish analyst targets near $35.60 offer upside, but high valuation ratios (P/E of 57.14) and recent earnings misses heighten risk. Key risks include margin pressure from GLP-1 investments and ongoing legal investigations. Wall Street sentiment is cautious, with 65% hold ratings, suggesting patience for profitability improvements.